Michael Recht

Michael Recht, MD, PhD, MBA, is a Clinical Professor of Pediatrics at Yale University School of Medicine, specializing in pediatric hematology with a focus on bleeding and clotting disorders. He leads the Hemophilia Treatment Center and has extensive experience in over 110 clinical trials, particularly in gene therapy for hemophilia. Additionally, he serves as Chief Medical and Scientific Officer at the National Hemophilia Foundation, shaping research strategies to advance treatments for bleeding disorders.

Education & Training:

• MD and PhD from University of Wisconsin-Madison (1992 and 1990)
• Pediatrics Residency and Pediatric Hematology-Oncology Fellowship at Yale New Haven Hospital/Yale School of Medicine (1995–1998)
• MBA from Oregon Health & Science University/Portland State University (2016)

Research Focus: Dr. Recht’s work centers on hemophilia, gene therapy, and clinical trials. His contributions include pioneering gene therapy studies and advancing evidence-based guidelines for hemophilia management. He leads initiatives like the American Thrombosis and Hemostasis Network Data Commons to enhance collaborative research.

Publications & Clinical Trials: His recent work emphasizes long-term outcomes of gene therapies (e.g., etranacogene dezaparvovec) and the efficacy of treatments like eptacog beta for bleeding events. He also evaluates real-world data through studies like the ATHNdataset.

Professional Roles: He advises on global hemophilia treatment guidelines and chairs the National Hemophilia Foundation’s research strategic initiatives. His leadership bridges academic medicine and nonprofit healthcare advocacy.

Awards & Honors: Not explicitly listed in provided texts, but his extensive contributions suggest recognition in hematology and clinical research.